RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
          펼치기
        • 주제분류
        • 발행연도
          펼치기
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • 사용자경험 리서치를 통한 유아용 인터렉티브 TV 연구

        전은용(Eunyong Jeon),윤주현(Ju-Hyun Eune) 한국HCI학회 2009 한국HCI학회 학술대회 Vol.2009 No.2

        에듀테인먼트는 유아용 인터렉티브 TV 를 연구하는데 있어서 가장 중요한 요소 중 하나이며, 유아교육시장에서의 이와 관련된 연구는 시장성으로나 소비자 수요 측면에서 큰 비중을 차지하고 있다. 이 연구의 목적은 아이들의 생활, 행태를 관찰, 조사 분석하여 발견된 중요한 요소들이 가지는 교육적 효과를 디자인을 통해 적용하여 에듀테인먼트 효과가 최대화된 유아용 인터렉티브 TV 를 위한 새로운 아이디어를 제시할 수 있도록 하고자 함이다. 아이들의 노는 모습-책 읽기, 음악듣기, 장난감가지고 놀기 등-아이들이 접하는 미디어들의 관찰을 통해 교육적 목적으로 환영 받지 못하는 TV 를 신뢰할 수 있는 매체로 재해석 하기 위하여 새로운 개념의 단서를 찾고자 하였다. 새로운 서비스를 제안하기 위하여 사용자가 기존의 미디어를 통해 상호작용하는 행태를 관찰, 분석하여 그 결과를 유아용 인터렉티브 TV 의 서비스를 위한 사용자 경험 정보 구조와 그 경험을 가능하게 하는 Input 요소를 통한 인터렉션 방법의 제안을 함께 하였다. 본 연구에서 제시된 콘텐트의 경험구조와 그와 연동 가능한 input device 를 통해 좀 더 창의적인 상호작용이 가능한 유아용 인터렉티브 TV 를 위한 콘텐트 디자인이 가능할 것으로 생각된다. 초기의 TV 에서 IPTV 까지 TV 는 변천을 거듭하여 왔고 네트워크라는 인프라의 중심에 서게 되면서 인터렉션 요소를 통해 에듀테인먼트 효과가 극대화 될 수 있는 매체로써 새로운 전기를 맞이하게 될 것으로 예상된다. Edutainment is the one of important factors to study interactive TV for children, and it is a big portion in kid's marketing and education market as well. The aim of this study is to design interactive TV for children to maximize edutainment effects by researching children's behaviors. The analysis of children's behaviors with educational effects should be focused to apply designing user experience to propose new ideas of interactive TV. Through observing children's behaviors and interaction with other media, such as books, CD players, digital camera, and so on, TV can be reanalyzed as reliable media, which is creative interactive TV for children with proposals of user experience structure and interaction solution. TV has been changed from analog TV to IPTV and it will be different with network and interactive solution.

      • 폴리이미드 나노 구조물을 이용한 유전자 분리기술 향상

        전은용(Eunyong Jeon),이정훈(Junghoon Lee) 대한기계학회 2011 대한기계학회 춘추학술대회 Vol.2011 No.10

        Gel electrophoresis is the major DNA separation method in biology and biomedical engineering. This method, however, has primary disadvantage such as low resolution, low separation speed and a large amount of sample consumption. Recently, several group developed Microfluidic chip using artificial Rod matrix instead of Agarose gel. According to the research, artificial Rod has advantage which is Channel Miniaturization, high separation speed. Our research group designed grass-like polyimide structure which we call Nano-grass (NG) for preparing sieving matrix. The NG pattern easily formed by photolithograph and plasma etch process without mask layer. Miniaturization and simple fabrication are critical issues in the microchip separation device. Moreover we can control height and diameter of NG, so controllable sieving matrix creates great opportunity to increase variation for different size of DNA

      • KCI등재

        극소 저체중 신생아의 예제제 정맥영양수액 공급에 의한 임상적 효과 평가

        성지현,임나리,전은용,이후경,성세인,민명숙 한국병원약사회 2021 병원약사회지 Vol.38 No.4

        Background : Preterm infants including very low birth weight infants (VLBWIs) and extremely low birth weight infants (ELBWIs) have high rates of protein turnover and low nutrient reserves. Therefore, parenteral nutrition (PN) should be initiated within 24 hours after birth if it is anticipated that they will be unable to tolerate enteral feeding for more than 2 to 3 days. However, in our institution, in cases of babies born on holidays and weekends, it is difficult to supply individualized PN including amino acids. So we supply starter PN (SPN) every Saturday and holiday, for use in case of emergency. We intended to evaluate the clinical efficacy of SPN on short-term growth and nutritional supply, especially for preterm infants. Methods : We retrospectively reviewed the medical records of preterm infants with a birth weight of less than 1,500 g who were born and admitted to the neonatal intensive care unit (NICU) of the Samsung Medical Center between March 2015 and May 2020. The patients were categorized into two groups according to whether they received SPN or not. We compared perinatal characteristics, nutrition supply, anthropometric measurements, and laboratory findings between the two groups. Results : Of the 82 patients, 40 infants were in the SPN group. Gestational age (p<0.001) and one minute Apgar score (p<0.001), and calories supplied over the first two weeks were lower in the SPN group (p=0.014). However, the rate of weight gain was higher in the SPN group (p=0.007). Most laboratory test results were significantly different between the two groups. Conclusion : SPN can improve the short-term growth of preterm infants. Lower gestational age seems to be the cause of relatively high values of laboratory test results including BUN and blood glucose as well as low caloric intake in the SPN group.

      • 의약품의 표시기재 현황과 개선방안 -주사제 및 PTP 경구제를 중심으로-

        김정현,홍수연,전은용,이후경,인용원,손기호 한국병원약사회 2007 병원약사회지 Vol.24 No.3

        Medical information descriptions for direct containers are meant to foster the safe and effective use of medicine, and the guidelines for their formulation are stipulated in the relevant pharmaceutical affairs laws. However, legally, all information except the name of the product and manufacturing company is omittable in cases in which the size of the container is not sufficient for the inclusion of information. This shortage of description results in mistakes in the preparation of medicine, and also contributes to difficulties in medicine management. These problems constitute the motivation for the writing of this paper. First, we have assessed the current status of information description for both injection and PTP products. We have also proposed a few hypothetical solutions for the problems described above. Our investigation was conducted with 192 types of vial and ampule injection products and 195 types of PTP product, all of which were prescribed at the Samsung Medical Center. For those products, we assessed the external packaging and direct containers, to determine whether they described the following 6 items: the names of the elements of the medicine, the product name, the manufacturing company, the expiration date, and the manufacturing sequence number. In our investigation, it was shown that in the external packaging of the injection products, the description of all items was included at a rate of 100%, but complete descriptions were observed in only 68.5% (200 types of product) of the direct containers. Among the examined direct containers, the rate at which the expiration date was included was lower than that for the others products: 96.6% (169 over 175 products) for vials and 51.3% (60 over 117 products) for ampules. For PTP, the description rate of all items was 100% for all items in the case of external packaging, whereas it was 59.5% (116 products) in the case of direct containers, and only 6.2% (12 products) when the medicine was packaged in single tablets. The rates at which the names of elements, product name, and elemental contents were included were 71.8% (140 products), 100% (195 products), and 86.2% (168 products), respectively, for PTP. In particular, all three items were described in only 37.4% of cases in which the medicine was packaged in the form of a single tablet (73 products). In conclusion, the description rate is currently quite good for the items, which are mandatorily specified in the pharmaceutical affairs law, but is not as good for the items that may be omitted in exceptional cases. Therefore, it is necessary to consider whether these omissions are acceptable or unacceptable on a case-by-case basis. Even though direct containers and packages are small, it is imperative that the six items specified in this research be included on those packages, so that the safety and management of the medicine can be guaranteed. In this manner, we can ensure safe and effective medicine usage. To this end, it is also necessary that the government and associated organizations be continuously reminded of these problems, and finally, that the current laws in this regard be amended.

      • KCI등재

        면역관문억제제 투여 환자의 간기능 이상반응 분석

        박지현,김정현,전은용,이후경,민명숙 한국병원약사회 2022 병원약사회지 Vol.39 No.4

        Background : Immune check point inhibitors can cause immune-related adverse events. Among them, hepatic adverse events are usually mild. However, in rare cases, fatal and severe adverse events might occur. The objective of this study was to evaluate the incidence, time of occurrence, and risk factors of hepatic adverse event in patients treated with immune check point inhibitors. Methods : Electronic medical records of patients aged 18 years or older who were treated with immune check point inhibitors in Samsung Medical Center Hematooncology from June 1, 2020 to November 31, 2020 were retrospectively reviewed. Results : In this study, a total of 702 patients were evaluated, including 526 (74.9%) males and 176 (25.1%) females. Hepatic adverse events were identified in 327 (46.6%) patients (Grade Ⅰ, 257 patients, 78.6%; Grade Ⅱ, 35 patients, 10.7%; Grade Ⅲ, 30 patients, 9.2%; Grade Ⅳ, 5 patients, 1.5%). The median time when AST/ALT reached the maximum level after first administration of immune checkpoint inhibitors was 94 days (range, 7-1211 days). In all hepatic adverse events, patients who were younger than 65 years-old had higher risk of hepatic adverse events (OR: 1.712; 95% CI: 1.265-2.317, p < 0.001). Risk factor for hepatic adverse events above grade Ⅱ were under 65 years-old (OR: 1.854; 95% CI: 1.090-3.352, p = 0.023), combined PPI (OR: 2.064; 95% CI: 1.183-3.600), and other cancers (i.e., bladder cancer) (OR: 2.988, 95% CI: 1.004-8.896, p = 0.049) based on classification criteria in this study. Conclusion : Based on this result, most hepatic adverse events were mild. However, in 10% of patients, moderate or higher hepatic adverse events were observed. The time of occurrence was about 3 months after first administration. In addition, the younger than 65 years-old age, the higher the likelihood of hepatic adverse events, and the severity of adverse events in the under 65-year-old, PPI coadministration group, and specific cancer may increase, requiring careful monitoring.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼